Articles About Biotech Investing

The Latest Nobel Prize in Chemistry Is Hiding A Massive Moneymaking Opportunity

0 | By Michael A. Robinson

When it comes to scientific breakthroughs, the only thing better than a Nobel Prize is a Nobel Prize with its own hidden way to beat the market.

And that’s exactly the opportunity I’m presenting to you today.

It comes to us from the field of gene editing, which actually allows doctors to edit material in human DNA to combat disease.
As a biotech investor, I have followed this field for many years.

While it stretches back to the 1970s, two women recently shared a Nobel Prize in Chemistry for turning the field on its head.

They developed what’s known as Crispr-Cas9, which allows genomic editing at the embryonic level. The Nobel committee described the science as “rewriting the code of life.”

The market for direct use of this platform is growing at 16% per year and will soon be worth roughly $10 billion.

And there is a firm pioneering this field that is beating the broad market by more than 45%…

This One Company Has What Every Pharma Giant Needs – And They Could Double Your Money In Just Three Years

1 | By Michael A. Robinson

Back in mid-March, I wrote a two-part series on the hunt for a COVID-19 vaccine.

You can read the first part of that series here and the second part right here.

At the time, I noted there were roughly a dozen or so companies involved racing to find a way to stop the deadly disease.

And while that sounded like a lot of scientific effort at the time, it turns out my analysis was too conservative.

We now have well over 100 research teams around the world scrambling for a vaccine or a drug that treats the disease.

Of those, at least two dozen hail from biotech or drug firms, many of them publicly traded.

I don’t know about you but I would love to get in on all that action with a great tech-centric firm that has superior earnings and price appreciation ahead.

And that is just what I’m going to reveal today. Doubling its earnings every 18 months, this “Biotech Goldmine” is set to crush the overall market…

This One Investment Covers an Entire Necessary Sector – And It’s Fighting Against the Coronavirus

0 | By Michael A. Robinson

Amid Big Media’s saturation coverage of the coronavirus panic, an important new medical breakthrough received scant attention.

After all, TV, radio, websites, newspapers, magazines and social media were riveted with stories about the spread of the new pandemic.

But working quietly behind the scenes, a team from Stanford University reported a new breakthrough in anti-aging biotech.

Indeed, the team discovered a way to “reset” the age of human cells – all the way back to zero.

Make no mistake. This is a major step forward. At the very least it could help cut the impact of osteoporosis that afflicts older people and costs the U.S. more than $75 billion a year.

With that in mind, today I’m going to tell you why this new development is so important for medicine and show you a great biotech investment that should at least be on your bear market watchlist…

Get in On This Medical Breakthrough Before It Hits the Market

1 | By Michael A. Robinson

Imagine if all it took to treat a case of cancer was taking out the trash.

Now I want you to imagine that your body could do it all for you.

Hold that thought. Because a tech platform with that very task in mind is set to hit the market sooner than you think and will target a field set to be worth more than $160 billion.

Here’s the thing. Several life sciences firms are hard at work perfecting a new class of drugs known as “degraders.”

Let me explain. The root of many diseases lies in misguided proteins that bind together. So, the idea here is to come up with a new class of drugs that activate the body’s own molecular trash disposal systems.

This is one of the most exciting breakthroughs I’ve come across in many years. I believe it puts us close to the day when one pill can cure dozens, if not all, diseases.

And in a moment, I’m going to reveal a way investors can target the entire class of protein degraders with one savvy move

You Can Double Your Money Fighting the $1.1 Trillion Disease Killing America

0 | By Michael A. Robinson

I recently got the kind of news that no child wants to hear about an aging parent.

Here’s the thing, I count my blessings that my dad lived so long. After all, he’s a retired Marine Corps captain who saw three tours of combat, one in Korea and two in Vietnam.

Honestly he’s lucky he lived as long as he did. But that still doesn’t make the aging process any easier, at least not on the body.

He recently had a second knee replacement that didn’t go as well as planned. He also has swelling of the feet. His mobility is not all that great, and he can’t drive right now.

At 86, he recently learned he has congestive heart failure. That’s a condition in which the heart doesn’t pump as strongly as it should, leading to a buildup of fluids.

As such, my dad is part of a huge trend in America. Fact is, according to the American Heart Association, cardiovascular disease is set to have an economic impact of $1.1 trillion by 2035.

And today, I want to reveal a life sciences firm that is bringing badly needed relief to millions of heart patients, and show you five reasons why it’s set to double in as little as 3.5 years

The Answer to Big Pharma’s Biggest Problem Could Double Your Money in just Three Years

0 | By Michael A. Robinson

You could forgive drug and biotech executives for having a bad case of target fixation.

After all, they do work in a field that is filled with time-consuming and expensive headaches.

Consider that the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.

The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That’s a one-in-ten shot.

With such daunting data, it’s no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.

And with that goal in mind, I’ve uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector’s success.

It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months

It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months

The “Printing” Tech Tackling Heart Disease’s $400 Billion in Annual Costs

0 | By Michael A. Robinson

There’s a new cutting-edge tech breakthrough that could save the lives of six million Americans in a decade.

Yes, it is potentially a very powerful weapon in the fight against heart disease, which the U.S. Centers for Disease Control and Prevention says causes one in four deaths each year.

Ironically, the technology is in a sector deeply out of favor with Wall Street.

But that’s just fine with us. At Strategic Tech Investor, we know the huge profit potential in bucking the Street’s herd mentality.

And you couldn’t pick a more exciting field than 3D-printed human organs.

Here’s the thing. Scientists in Israel printed a tiny heart in April, complete with blood vessels, using a patient’s cells.

Even better, they pulled off this amazing achievement in just three hours.

That’s why today, I’m going to show you what I believe is the best market-crushing play on the future of 3D printing tech used to save lives…

Check it out

The Best Way to Play the $2.6 Billion Med Tech Updraft

0 | By Michael A. Robinson

My wife Tracy just got the kind of news from her dentist that no one really wants to hear.

Turns out she has a crack in one of her teeth and needs to have a crown installed.

On the other hand, she did find out something very interesting. Her dentist is qualified to install Invisalign braces.

As the term implies, these are not the metal wireworks that can make people feel embarrassed when they smile.

Instead, they are clear mouth guards you wear most of the day. It’s a great solution for adults like Tracy.

She had braces as a kid, but over the years stopped wearing her retainer. The result is that some of her lower teeth have drifted and she’d like to have that corrected.

There’s a lot more going on here than simple pride. It’s part of a market that is doubling every nine years, and will soon be worth $2.6 billion.

Today, I want to show you the best way to play this medtech trend with a stock that is beating the market by 74.5%…

Check it out…

The New American Dream… for as Little as $50

0 | By Michael A. Robinson

I’ve got some very exciting investment news for you today.

See, on June 25th, the renowned investor and world famous “Shark” Robert Herjavec is coming to Money Morning to unveil a radical new way to achieve the American Dream.

Working hard and living within your means are admirable lifestyle choices, for sure. But the millionaire next door is going to look a lot different now.

That’s because, from here on out, all you’ll really need is access to a small group of smart, dedicated, and industrious people who do all the heavy lifting on your behalf.

Oddly enough, they’re incredibly willing to do it. In fact, when it comes to you getting rich, these people are wildly enthusiastic about it, as you’ll see in this first-of-its-kind online event.

The World’s First $1B Cannabis Drug – and 2 More Biotech Blockbusters

1 | By Michael A. Robinson

To hear Wall Street tell it, AbbVie Inc. (NYSE: ABBV) drove right into a ditch last month.

Here’s the thing. The company announced results of a Phase 2 trial on March 22 that were disappointing but hardly fatal. The results mean AbbVie won’t seek fast-track approval for its promising antibody-drug conjugate, Rova-T, but it still expects to be able to take it to market in the near future.

Wall Street overreacted – no surprise there – and AbbVie shares lost 15% in three sessions.

Here’s the thing. Wall Street’s overreaction to AbbVie’s disappointing U.S. Food and Drug Administration trial results weren’t the only reason for its share-price plummet.

You see, though it shouldn’t be, biotech is in the dog house – and investors are primed to punish stocks in the sector for just about anything.

In fact, since hitting a three-year high in August 2015, the Nasdaq Biotech Index is off 6%. During that stretch, the S&P 500 is up nearly 35%.

Biotech is down for three main reasons. Wall Street is worried about…